Hong Kong – – September 28, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) reported a 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) scores from a 28-day U.S. proof-of-concept trial of ASC50, an oral small molecule IL-17A inhibitor positioned as a needle-free alternative to injectable antibody therapies for plaque psoriasis.

San Diego – September 28, 2026 -- Viking Therapeutics, Inc. (Nasdaq: VKTX) has closed concurrent upsized public offerings totaling approximately $575.0 million in gross proceeds, funding to accelerate its late-stage obesity drug pipeline.

Conshohocken, Pa. – September 28, 2026 -- TJP, an independent agency focused on value and patient access for life sciences, has acquired Evolution Consulting & Research, a market research organization serving global pharmaceutical and biotech clients.

North Chicago, Ill. – – September 28, 2026 -- AbbVie (NYSE: ABBV) has secured U.S. FDA approval for JUVMO (tavapadon), the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease, with commercial availability set for October 2026.

Piscataway, N.J. – September 28, 2026 -- Sampled has secured a five-year contract worth up to $27.1 million from the Department of Veterans Affairs to provide genomics analyses for the Million Veteran Program (MVP), one of the world's largest research initiatives of its kind.

Indianapolis – September 28, 2026 -- Eli Lilly and Company (NYSE: LLY) launched the Lilly Change the Course Commitment on Sept. 28, targeting treatment parity for diabetes and obesity patients between high-income countries and resource-limited settings by 2040. Today, for every four patients in high-income countries who access Lilly's diabetes and obesity medicines, only one patient in low- and middle-income countries (LMICs) can reach them.

Friendswood, Texas – September 28, 2026 -- Castle Biosciences, Inc. (Nasdaq: CSTL) said a new peer-reviewed study found its TissueCypher Barrett's Esophagus Test prompted clinicians to change management recommendations in 90% of cases involving patients with non-dysplastic Barrett's esophagus (NDBE).

The case series, published in Foregut: The Journal of the American Foregut Society, evaluated 30 NDBE patients tested as part of clinical care at Keck Medical Center of the University of Southern California (USC).

Shanghai – – September 28, 2026 -- MOYOM Biotech, a Chinese developer of regenerative aesthetic biomaterials, has secured a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital, to fund international expansion of its flagship CaHA-based implant brand Aphranel®.

South San Francisco, Calif. – September 28, 2026 -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA) promoted Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.

Tokyo – September 28, 2026 -- SOLA Biosciences Japan GK has secured a grant of approximately 6 billion yen over five years from Japan's Agency for Medical Research and Development (AMED) to advance SOL-257, a gene therapy candidate targeting the TDP-43 protein implicated in amyotrophic lateral sclerosis (ALS). The award, granted under AMED's Strengthening Program for Pharmaceutical Startup Ecosystem, was announced June 5, 2026, and positions SOLA Japan as the company's central development hub for the program.